Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia

NCT06721013 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06721013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06721013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 30, 2025
Completion date
February 28, 2029
Enrollment
68 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia (itp)